These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28580181)

  • 1. Intercellular Adhesion Molecular-5 as Marker in HIV Associated Neurocognitive Disorder.
    Yuan L; Wei F; Zhang X; Guo X; Lu X; Su B; Zhang T; Wu H; Chen D
    Aging Dis; 2017 May; 8(3):250-256. PubMed ID: 28580181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy.
    Pollard JR; Eidelman O; Mueller GP; Dalgard CL; Crino PB; Anderson CT; Brand EJ; Burakgazi E; Ivaturi SK; Pollard HB
    Front Neurol; 2012; 3():181. PubMed ID: 23293627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship of CSF and plasma cytokine levels in HIV infected patients with neurocognitive impairment.
    Yuan L; Liu A; Qiao L; Sheng B; Xu M; Li W; Chen D
    Biomed Res Int; 2015; 2015():506872. PubMed ID: 25821806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals.
    Pérez-Santiago J; De Oliveira MF; Var SR; Day TRC; Woods SP; Gianella S; Mehta SR
    J Neurovirol; 2017 Apr; 23(2):283-289. PubMed ID: 27921220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
    Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
    AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.
    McGuire JL; Gill AJ; Douglas SD; Kolson DL;
    J Neurovirol; 2015 Aug; 21(4):439-48. PubMed ID: 25776526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
    Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection.
    Pérez-Santiago J; Schrier RD; de Oliveira MF; Gianella S; Var SR; Day TR; Ramirez-Gaona M; Suben JD; Murrell B; Massanella M; Cherner M; Smith DM; Ellis RJ; Letendre SL; Mehta SR
    J Neurovirol; 2016 Apr; 22(2):191-200. PubMed ID: 26428514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
    Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
    J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND).
    Gougeon ML; Poirier-Beaudouin B; Durant J; Lebrun-Frenay C; Saïdi H; Seffer V; Ticchioni M; Chanalet S; Carsenti H; Harvey-Langton A; Laffon M; Cottalorda J; Pradier C; Dellamonica P; Vassallo M
    Heliyon; 2017 Feb; 3(2):e00245. PubMed ID: 28224137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
    Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
    BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (1→3)-β-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy: A Cohort Study.
    Hoenigl M; de Oliveira MF; Pérez-Santiago J; Zhang Y; Morris S; McCutchan AJ; Finkelman M; Marcotte TD; Ellis RJ; Gianella S
    Medicine (Baltimore); 2016 Mar; 95(11):e3162. PubMed ID: 26986173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals.
    Suh HS; Lo Y; Choi N; Letendre S; Lee SC
    J Neuroinflammation; 2015 Apr; 12():72. PubMed ID: 25890304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.
    Anderson AM; Lennox JL; Mulligan MM; Loring DW; Zetterberg H; Blennow K; Kessing C; Koneru R; Easley K; Tyor WR
    J Neurovirol; 2017 Feb; 23(1):106-112. PubMed ID: 27400930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.
    Spudich S; Robertson KR; Bosch RJ; Gandhi RT; Cyktor JC; Mar H; Macatangay BJ; Lalama CM; Rinaldo C; Collier AC; Godfrey C; Eron JJ; McMahon D; Jacobs JL; Koontz D; Hogg E; Vecchio A; Mellors JW
    J Clin Invest; 2019 Jul; 129(8):3339-3346. PubMed ID: 31305262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.
    Ellis RJ; Hsia K; Spector SA; Nelson JA; Heaton RK; Wallace MR; Abramson I; Atkinson JH; Grant I; McCutchan JA
    Ann Neurol; 1997 Nov; 42(5):679-88. PubMed ID: 9392566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
    Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
    Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
    J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.